Novel phenotype-driven pharmacogenetics of irinotecan and cisplatin
MetadataShow full item record
We investigated the genetics of adverse drug reactions to chemotherapy which up until now have been unpredictable in patients. We used recombinant congenic (RC) mouse models in order to identify the genes responsible for the adverse drug reactions to irinotecan and cisplatin. We found that non-PK/PD genes are responsible for the body weight loss seen in irinotecan treatment and the nephrotoxicity from cisplatin treatment. This indicates that there are presently unknown genes responsible for ADRs. By identify these genes in mice, we will then be able to analyze their human homologues and better predict toxicities in patients.